{"DataElement":{"publicId":"8027502","version":"1","preferredName":"Iobenguane Therapeutic Procedure Children's Oncology Group Approval Healthcare Facility Other Specify Text","preferredDefinition":"Text field to specify another location of a healthcare facility site approved by Children's Oncology Group (COG) for Iobenguane treatment.","longName":"MIBG_COG_APPR_FACIL_OTH_SP_TXT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"8027501","version":"1","preferredName":"Iobenguane Therapeutic Procedure Children's Oncology Group Approval Healthcare Facility","preferredDefinition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers._Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval._The buildings and organizations where healthcare services are provided.","longName":"5740686v1.0:8027499v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5740686","version":"1","preferredName":"Iobenguane Therapeutic Procedure","preferredDefinition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"C87757:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iobenguane","conceptCode":"C87757","definition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C754BE0-F5E0-7E5F-E053-F662850A6631","latestVersionIndicator":"Yes","beginDate":"2017-04-05","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-05","modifiedBy":"ONEDATA","dateModified":"2017-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"8035897","version":"1","preferredName":"Children's Oncology Group Approval Healthcare Facility","preferredDefinition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.:Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.:The buildings and organizations where healthcare services are provided.","longName":"C39353:C25425:C21541","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Children's Oncology Group","conceptCode":"C39353","definition":"An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Approval","conceptCode":"C25425","definition":"Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Healthcare Facility","conceptCode":"C21541","definition":"The buildings and organizations where healthcare services are provided.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7AA10F5-3A13-5296-E053-4EBD850A2F12","latestVersionIndicator":"Yes","beginDate":"2022-02-10","endDate":null,"createdBy":"TITARENI","dateCreated":"2022-02-10","modifiedBy":"ONEDATA","dateModified":"2022-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008543","version":"1","preferredName":"Geographic Locations","preferredDefinition":"all components of an address, including building number, street name and type, city, state, postal code, and country.","longName":"GEO_LCTNS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227ED46-D8B2-4A76-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7246B7C-7EBE-214B-E053-4EBD850A1DC1","latestVersionIndicator":"Yes","beginDate":"2022-02-03","endDate":null,"createdBy":"TITARENI","dateCreated":"2022-02-03","modifiedBy":"CLOHNES","dateModified":"2022-09-07","changeDescription":"02/03/2022 created to COG to help replace retired CDEs 5782168 and 5782169_Irina Titarenko.","administrativeNotes":"9/7/22 Released DEC per AK for COG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2857322","version":"1","preferredName":"Other Specify Text","preferredDefinition":"The free text field that describes another response when other is chosen from a list of values.","longName":"OTHR_SPEC_TXT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2857047","version":"1","preferredName":"Other Specify Text","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.:Text; the words of something written.","longName":"C17649:C25685:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"660AABE0-46ED-4890-E040-BB89AD431D5B","latestVersionIndicator":"Yes","beginDate":"2009-03-26","endDate":null,"createdBy":"SCOTTLO","dateCreated":"2009-03-26","modifiedBy":"ONEDATA","dateModified":"2009-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"6648A78E-AB33-047A-E040-BB89AD4324AB","latestVersionIndicator":"Yes","beginDate":"2009-03-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-03-29","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/22/17 tt transferred context, added registration status and CSI per Round 5 finalization task. Modified for The Cancer Genome Atlas (TCGA) by request of T. Lichtenberg (JP) 12/2010.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If Other COG approved MIBG si","type":"Preferred Question Text","description":"If Other COG approved MIBG sites, specify:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D71DF4AE-4A4D-0B18-E053-4EBD850A2B87","latestVersionIndicator":"Yes","beginDate":"2022-02-03","endDate":null,"createdBy":"TITARENI","dateCreated":"2022-02-03","modifiedBy":"CLOHNES","dateModified":"2022-09-07","changeDescription":"02/03/2022 created for COG to replace the retired CDEs 5782168 and 5782169_Irina Titarenko","administrativeNotes":"9/7/22 Released CDE per AK for COG cjl;","unresolvedIssues":null,"deletedIndicator":"No"}}